Join Growin Stock Community!

達邦蛋白6578.TW Overview

TW StockAgr. Science & Tech.
(No presentation for 6578)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

達邦蛋白（6578）Overall Performance

達邦蛋白（6578）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

達邦蛋白（6578） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

達邦蛋白（6578）Key Information

達邦蛋白（6578）Profile

DaBomb Protein Biotech Corp., a specialized biotech company, primarily engages in the development of antibiotics alternatives in animal health industry. It offers plant protein, including DaBomb-P (Aqua) and DaBomb-P (Livestock); antibiotics alternatives, such as DBT-100 HT and DBT-100 LS; and pet care products comprising LACTOTIDES HEALTH A+ and Liqui-TIDE bandages. The company was formerly known as DaBomb Protein Corp. and changed its name to DaBomb Protein Biotech Corp. in October 2023. DaBomb Protein Biotech Corp. was founded in 2001 and is based in Tainan, Taiwan.

達邦蛋白（6578）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
21.72%
Net Margin
-7.73%
Revenue Growth (YoY)
-13.07%
Profit Growth (YoY)
-6.99%
3-Year Revenue Growth
-7.48%
3-Year Profit Growth
45.93%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
21.72%
Net Margin
-7.73%
Revenue Growth (YoY)
-13.07%
Profit Growth (YoY)
-6.99%
3-Year Revenue Growth
-7.48%
3-Year Profit Growth
45.93%
default symbol

6578

達邦蛋白

18.20D

-1.37%

(-0.01)

  • When is 6578's latest earnings report released?

    The most recent financial report for 達邦蛋白 (6578) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6578's short-term business performance and financial health. For the latest updates on 6578's earnings releases, visit this page regularly.

  • What is the operating profit of 6578?

    According to the latest financial report, 達邦蛋白 (6578) reported an Operating Profit of -21.07M with an Operating Margin of -30.55% this period, representing a decline of 400.76% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6578's revenue growth?

    In the latest financial report, 達邦蛋白 (6578) announced revenue of 68.97M, with a Year-Over-Year growth rate of 21.09%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6578 have?

    At the end of the period, 達邦蛋白 (6578) held Total Cash and Cash Equivalents of 192.57M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6578 go with three margins increasing?

    In the latest report, 達邦蛋白 (6578) did not achieve the “three margins increasing” benchmark, with a gross margin of 22.91%%, operating margin of -30.55%%, and net margin of -17.91%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6578's profit trajectory and future growth potential.

  • Is 6578's EPS continuing to grow?

    According to the past four quarterly reports, 達邦蛋白 (6578)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.17. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6578?

    達邦蛋白 (6578)'s Free Cash Flow (FCF) for the period is 252.63M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 16,952.9% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.